Inferra AIResearch Tools

Inferra AI / Company / IMVT

Immunovant, Inc.

IMVT · Health Care

Last earnings Aug 6, 2026

AI analysis

Q2 2025 · reported Nov 10, 2025

Based on: Earnings release + parent 8-K + 10-K — transcript not held

No extracted figures held

The event-summary record for this company carries no extracted figures, so the brief and charts cannot be drawn yet. The summary below and the held documents are the record for this event.

Guidance · company-stated

No guidance located in the held release

Next earningsNo verified date on fileNo date is estimated or imported

Capital allocation

Raising additional funds through debt financings may involve restrictive covenants and raising funds through lending and licensing arrangements may restrict our operations or require us to relinquish proprietary rights.

General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

Immunovant expects to report results from the open-label portion of the potentially registrational trial of IMVT-1402 in D2T RA and topline results from the proof-of-concept trial of IMVT-1402 in CLE in calendar year 2026

Based on: Earnings release + parent 8-K + 10-K — transcript not held

Guidance & outlook

No guidance located in the held release

Capital allocation

Raising additional funds through debt financings may involve restrictive covenants and raising funds through lending and licensing arrangements may restrict our operations or require us to relinquish proprietary rights.

SEC original ↗Immunovant, Inc. — 10-K Annual report10-KMay 20, 2026

Strategy & priorities

The decrease was primarily due to the streamlining of administrative processes to drive effective cost management strategies.

SEC original ↗Immunovant, Inc. — Earnings release (8-K exhibit)EX-99Nov 10, 2025

International expansion of our business exposes us to business, legal, regulatory, political, operational, financial and economic risks associated with conducting business outside of the U.

SEC original ↗Immunovant, Inc. — 10-K Annual report10-KMay 20, 2026

7 Table of Contents Business Strategy We are pursuing a broad anti-FcRn strategy based on the potential best-in-class profile of IMVT-1402 for the treatment of IgG-mediated autoimmune diseases.

SEC original ↗Immunovant, Inc. — 10-K Annual report10-KMay 20, 2026

To execute our strategy, we plan to: Prioritize areas of significant unmet medical need where IMVT-1402 could potentially be first- and best-in-class.

SEC original ↗Immunovant, Inc. — 10-K Annual report10-KMay 20, 2026

Focus on rapid clinical execution as a key priority.

SEC original ↗Immunovant, Inc. — 10-K Annual report10-KMay 20, 2026

Risks & headwinds

All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Immunovant expected.

SEC original ↗Immunovant, Inc. — Earnings release (8-K exhibit)EX-99Nov 10, 2025

These and other risks and uncertainties are more fully described in Immunovant s periodic and other reports filed with the Securities and Exchange Commission (SEC), including in the section titled Risk Factors in Immunovant s Annual Report on Form 10-K filed with the SEC on May 29, 2025, and Immunovant s subsequent filings with the SEC.

SEC original ↗Immunovant, Inc. — Earnings release (8-K exhibit)EX-99Nov 10, 2025

LEGAL PROCEEDINGS 102 ITEM 4.

SEC original ↗Immunovant, Inc. — 10-K Annual report10-KMay 20, 2026

Table of Contents CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K for the fiscal year ended March 31, 2026 (this Annual Report ) contains forward-looking statements that involve substantial risks and uncertainties.

SEC original ↗Immunovant, Inc. — 10-K Annual report10-KMay 20, 2026

These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements.

SEC original ↗Immunovant, Inc. — 10-K Annual report10-KMay 20, 2026

In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all.

SEC original ↗Immunovant, Inc. — 10-K Annual report10-KMay 20, 2026

Documents

Earnings deck slides

0 decks with slide view

Immunovant, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care

Filings

32 documents

Earnings releases

6 documents

Presentations

1 document

Transcripts

0 documents

No transcripts for Immunovant, Inc. are held in this edition of the library.

Mentioned by

1 company

Other tracked companies whose held documents mention Immunovant, Inc. by name or ticker. A mention is counted once per document, from the document text the library holds.

See also the earnings calendar for every tracked company’s next earnings date.